Company / R&D per Share
RAPT Therapeutics, Inc. R&D per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.63
FY2024
5-year range
$1.88 / $2.63
FY2020-FY2024
Trend
-0.2%
vs FY2023
Sector context
#76 of 204
Health Care
What the data says
At $2.63, RAPT Therapeutics, Inc.'s r&d per share ranks #76 of 204 in the Health Care sector. R&D per Share has fluctuated over the past 7 years, ranging from $1.88 in FY2020 to $51.05 in FY2018.
Based on SEC 10-K filings.
2.63 in FY2024 with a 5-year CAGR of -20.0%.
Improved from $2.06 to $2.63 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +8.1%
- 5-Year CAGR
- -20.0%
- 10-Year CAGR
- -
Sector benchmark
#76 of 204 in Health CareTop 37% of 204This company $2.63 Sector average $34.99
▼
-92.5% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 0.2% year-over-year.
- Ranks #76 out of 204 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.63 | -0.2% |
| FY2023 | $2.63 | +27.8% |
| FY2022 | $2.06 | -0.9% |
| FY2021 | $2.08 | +10.4% |
| FY2020 | $1.88 | -76.5% |
| FY2019 | $8.03 | -84.3% |
| FY2018 | $51.05 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026